Biosimilar bidding in centralized tenders in Norway

Our objective is to study the competition effect of biosimilar entry in centralized tenders for an expensive category or drugs - TNF-inhibitors. We use monthly observations of prices and volumes for all brands and biosimilars in this drug category in Norway, covering the period from Jan. 2006 to Dec. 2016. Descriptive statistics and regression models are used to investigate the impact of biosimilars on the drug price and the effect of the number of brands on the intensity of competition. Both the entry of biosimilars and new branded drugs have increased competition and reduced prices. According to our estimates, an increase in the market share of biosimilars from 10 % to 60 %, will be accompanied with a 50 % reduction in the expected price. Only two years after entry, the first biosimilars in this drug category had gained a market share of 40 % in Norwegian hospitals. Although entry barriers for biosimilars are higher than for generics of chemical substances, significant cost savings are expected from patent expirations of expensive biologics as well. The centralized design of the tenders is an important institutional factor behind the strong competition effect. Published: Online January 2020

Profil Penggunaan Obat Antidotum Di Rumah Sakit Umum Daerah Undata Provinsi Sulawesi Tengah Periode 2016-2018

Antidotes drug is indicated in intoxication or poisoning patients, in addition to the antidote drugs, it can also be used as an appropriate therapeutic indication of his own medicine. The high increasing number of the antidote drug used every year in inpatient instalation Undata hospital, for exmple atropine, N-acetylcysteine and pyridoxine (vitamin B6). Therefore, this study aims to determine the percentage of drug use of antidote category indicated as an antidote therapy in Undata hospitals Central Sulawesi Province period 2016-2018. This is a descriptive study with retrospective approach and using purposive sampling techniques.The results showed that the sample size was 75 patients, with the percentage of drug use as antidotes category in Undata Hospital Central Sulawesi province period 2016-2018, namely pyridoxine (vitamin B6) of 49.33%, N-acetylcysteine drug of 42.66% and the atropine drug of 8%. The use of antidotes drug category are indicated as an antidote to the poisoning therapy drugs obtained 0%. It can be concluded that there is no antidote drug category that used as an antidote therapy on patients with drug poisoning in inpatient instalation Undata hospital Central Sulawesi Province Period 2016-2018.

Profil Penggunaan Obat Antidotum Di Rumah Sakit Umum Daerah Undata Provinsi Sulawesi Tengah Periode 2016-2018

Antidotes drug is indicated in intoxication or poisoning patients, in addition to the antidote drugs, it can also be used as an appropriate therapeutic indication of his own medicine. The high increasing number of the antidote drug used every year in inpatient instalation Undata hospital, for exmple atropine, N-acetylcysteine and pyridoxine (vitamin B6). Therefore, this study aims to determine the percentage of drug use of antidote category indicated as an antidote therapy in Undata hospitals Central Sulawesi Province period 2016-2018. This is a descriptive study with retrospective approach and using purposive sampling techniques.The results showed that the sample size was 75 patients, with the percentage of drug use as antidotes category in Undata Hospital Central Sulawesi province period 2016-2018, namely pyridoxine (vitamin B6) of 49.33%, N-acetylcysteine drug of 42.66% and the atropine drug of 8%. The use of antidotes drug category are indicated as an antidote to the poisoning therapy drugs obtained 0%. It can be concluded that there is no antidote drug category that used as an antidote therapy on patients with drug poisoning in inpatient instalation Undata hospital Central Sulawesi Province Period 2016-2018.